MCID: MNC007
MIFTS: 57

Monocytic Leukemia

Categories: Cancer diseases, Immune diseases, Blood diseases

Aliases & Classifications for Monocytic Leukemia

MalaCards integrated aliases for Monocytic Leukemia:

Name: Monocytic Leukemia 12 55 15 73
M5b Acute Differentiated Monocytic Leukemia 73
Schilling's Leukemia 12

Classifications:



External Ids:

Disease Ontology 12 DOID:8527
ICD10 33 C93.Z C93.Z0 C93
ICD9CM 35 206.8

Summaries for Monocytic Leukemia

MalaCards based summary : Monocytic Leukemia, also known as m5b acute differentiated monocytic leukemia, is related to leukemia, acute monocytic and acute monoblastic leukemia. An important gene associated with Monocytic Leukemia is KAT6A (Lysine Acetyltransferase 6A), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Lenograstim and Etoposide have been mentioned in the context of this disorder. Affiliated tissues include myeloid, monocytes and bone, and related phenotypes are Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) and hematopoietic system

Related Diseases for Monocytic Leukemia

Diseases in the Monocytic Leukemia family:

Leukemia, Acute Monocytic Adult Acute Monocytic Leukemia
Chronic Monocytic Leukemia Subacute Monocytic Leukemia

Diseases related to Monocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 313)
# Related Disease Score Top Affiliating Genes
1 leukemia, acute monocytic 34.1 CD14 KAT6A KIAA0100 KMT2A
2 acute monoblastic leukemia 31.5 CSF2 CXCL8 IL6 KMT2A
3 hematopoietic stem cell transplantation 30.0 IFNG IL6 TNF
4 langerhans cell histiocytosis 29.6 CSF1 CSF2 IFNG
5 thrombocytosis 29.1 CSF2 F3 IL6
6 graft-versus-host disease 29.0 IFNG IL1B IL6 TNF
7 obstructive jaundice 28.8 CXCL8 IL6 TNF
8 endocarditis 28.7 CXCL8 IL6 TNF
9 cytomegalovirus infection 28.6 CXCL8 IFNG IL6 TNF
10 aplastic anemia 28.4 CSF1 CSF2 IFNG IL6 TNF
11 gingivitis 28.4 CXCL8 IL1B IL6 TNF
12 respiratory failure 28.2 CXCL8 F3 TNF
13 prostatitis 28.2 CXCL8 IL1B IL6 TNF
14 pertussis 27.9 IL1B IL6 ITGAM JUN TNF
15 leukemia, acute myeloid 27.5 CASP3 CSF2 ITGAM JUN KAT6A KMT2A
16 myeloma, multiple 27.2 CASP3 CSF2 CXCL8 IL6 JUN TNF
17 adult acute monocytic leukemia 12.4
18 aleukemic monocytic leukemia cutis 12.3
19 chronic monocytic leukemia 12.2
20 subacute monocytic leukemia 12.2
21 leukemia 10.9
22 scorpion envenomation 10.6 IL6 TNF
23 fixed drug eruption 10.5 CASP3 IFNG
24 leukomalacia 10.5 IL6 TNF
25 angioimmunoblastic lymphadenopathy with dysproteinemia 10.5 IL6 TNF
26 systemic onset juvenile idiopathic arthritis 10.3 IL1B TNF
27 microscopic colitis 10.3 IFNG IL6 TNF
28 intermediate uveitis 10.3 IFNG IL6 TNF
29 spinal cord injury 10.3 CASP3 IL6 TNF
30 plasmodium vivax malaria 10.3 IFNG IL6 TNF
31 rasmussen encephalitis 10.3 IFNG IL6 TNF
32 paracoccidioidomycosis 10.2 IFNG IL6 TNF
33 mixed connective tissue disease 10.2 IFNG IL6 TNF
34 echinococcosis 10.2 IFNG IL6 TNF
35 reactive arthritis 10.2 IFNG IL6 TNF
36 melioidosis 10.2 IFNG IL6 TNF
37 periodontitis, chronic 10.2 IL1B IL6
38 human immunodeficiency virus infectious disease 10.2 IFNG IL6 TNF
39 spondyloarthropathy 10.2 IFNG IL6 TNF
40 critical limb ischemia 10.2 IL6 TNF
41 filariasis 10.2 IFNG IL6 TNF
42 parasitic protozoa infectious disease 10.2 IFNG IL6 TNF
43 campylobacteriosis 10.2 IFNG IL1B JUN
44 overnutrition 10.2 IL6 PPARG TNF
45 laryngitis 10.2 IL1B IL6 TNF
46 acute vascular insufficiency of intestine 10.2 IL1B IL6 TNF
47 poems syndrome 10.2 IL1B IL6 TNF
48 staphylococcal toxic shock syndrome 10.2 IFNG IL1B TNF
49 central nervous system vasculitis 10.2 IL1B IL6 TNF
50 osteosclerotic myeloma 10.2 IL1B IL6 TNF

Graphical network of the top 20 diseases related to Monocytic Leukemia:



Diseases related to Monocytic Leukemia

Symptoms & Phenotypes for Monocytic Leukemia

GenomeRNAi Phenotypes related to Monocytic Leukemia according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) GR00104-A-0 8.92 CSF2 CXCL8 TNF CASP3

MGI Mouse Phenotypes related to Monocytic Leukemia:

46 (show all 21)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.38 CSF2 CD14 CSF1 CASP3 F3 IL1B
2 cardiovascular system MP:0005385 10.37 CSF2 CSF1 CASP3 F3 IL1B IFNG
3 homeostasis/metabolism MP:0005376 10.37 CD14 CSF2 CSF1 CASP3 F3 IL1B
4 cellular MP:0005384 10.36 CSF2 CSF1 CASP3 IFNG F3 IL6
5 growth/size/body region MP:0005378 10.36 CD14 CSF2 CSF1 CASP3 IFNG F3
6 immune system MP:0005387 10.36 CSF2 CD14 CSF1 CASP3 F3 IL1B
7 behavior/neurological MP:0005386 10.34 CSF1 CASP3 CSF2 IFNG F3 JUN
8 integument MP:0010771 10.27 CSF2 CSF1 CASP3 F3 IL1B IFNG
9 mortality/aging MP:0010768 10.27 CD14 CSF1 CASP3 IFNG F3 IL1B
10 endocrine/exocrine gland MP:0005379 10.21 CSF1 CASP3 CSF2 IFNG JUN IL6
11 craniofacial MP:0005382 10.18 CSF2 CSF1 CASP3 IFNG IL1B KAT6A
12 nervous system MP:0003631 10.18 CSF2 CSF1 CASP3 F3 IL1B IFNG
13 embryo MP:0005380 10.17 CSF2 IFNG F3 JUN KAT6A PPARG
14 liver/biliary system MP:0005370 10.08 CSF1 IFNG IL6 KAT6A JUN KMT2A
15 muscle MP:0005369 10.03 CSF1 CASP3 IFNG F3 IL6 KMT2A
16 neoplasm MP:0002006 10.01 CSF2 F3 IL1B IFNG IL6 KMT2A
17 reproductive system MP:0005389 9.91 CSF1 CASP3 CSF2 IFNG IL6 KAT6A
18 no phenotypic analysis MP:0003012 9.87 CASP3 CSF1 IFNG JUN PPARG KMT2A
19 respiratory system MP:0005388 9.81 CD14 CSF2 CSF1 CASP3 F3 IFNG
20 skeleton MP:0005390 9.73 CSF2 CD14 CSF1 CASP3 IL1B IFNG
21 vision/eye MP:0005391 9.23 CASP3 CSF1 IFNG F3 JUN IL6

Drugs & Therapeutics for Monocytic Leukemia

Drugs for Monocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 217)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 135968-09-1
2
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
3
Amsacrine Approved, Investigational Phase 3 51264-14-3 2179
4
Mesna Approved, Investigational Phase 3 3375-50-6 598
5
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 147-94-4 6253
6
Clofarabine Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 123318-82-1 119182
7
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1,Early Phase 1 22916-47-8 4189
8
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 50-18-0, 6055-19-2 2907
9
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 55-98-1 2478
10
Idarubicin Approved Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58957-92-9 42890
11
Mitoxantrone Approved, Investigational Phase 3,Phase 2,Phase 1 65271-80-9 4212
12
Daunorubicin Approved Phase 3,Phase 2,Phase 1 20830-81-3 30323
13
Thioguanine Approved Phase 3,Phase 1 154-42-7 2723601
14
Aldesleukin Approved Phase 3,Phase 1,Phase 2 85898-30-2, 110942-02-4
15
alemtuzumab Approved, Investigational Phase 2, Phase 3,Phase 1 216503-57-0
16
Fludarabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 21679-14-1, 75607-67-9 30751
17
Hydrocortisone Approved, Vet_approved Phase 3 50-23-7 5754
18
Hydroxyurea Approved Phase 3 127-07-1 3657
19
Methotrexate Approved Phase 3,Phase 2,Phase 1 1959-05-2, 59-05-2 126941
20
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 1 50-02-2 5743
21
Melphalan Approved Phase 2, Phase 3,Phase 3,Phase 1 148-82-3 4053 460612
22
Azacitidine Approved, Investigational Phase 2, Phase 3,Phase 3,Phase 1 320-67-2 9444
23
Decitabine Approved, Investigational Phase 3,Phase 2,Phase 1 2353-33-5 451668
24
Carmustine Approved, Investigational Phase 3 154-93-8 2578
25
Arsenic trioxide Approved, Investigational Phase 2, Phase 3,Phase 1 1327-53-3 518740
26
Fluconazole Approved, Investigational Phase 3 86386-73-4 3365
27
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 468682 2826718
28
Cyproheptadine Approved Phase 3 129-03-3 2913
29
Histamine Approved, Investigational Phase 3 75614-87-8, 51-45-6 774
30
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 2,Phase 1 302-79-4 5538 444795
31
leucovorin Approved, Nutraceutical Phase 3,Phase 2,Phase 1 58-05-9 143 6006
32
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 2,Phase 1 59-30-3 6037
33
tipifarnib Investigational Phase 3,Phase 2,Phase 1 192185-72-1 159324
34 Staurosporine Experimental Phase 3,Phase 1 62996-74-1
35
Butyric Acid Experimental, Investigational Phase 3 107-92-6 264
36 Interleukin-2 Phase 3,Phase 1,Phase 2
37 Analgesics Phase 3,Phase 2,Phase 1
38 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
39 Gemtuzumab Phase 2, Phase 3,Phase 3,Phase 1
40 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
41 Dermatologic Agents Phase 3,Phase 2,Phase 1
42 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1
43 Vaccines Phase 3,Phase 1
44 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
45 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
46 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
47 Antibodies Phase 3,Phase 2
48 Immunoglobulins Phase 3,Phase 2
49 Antibodies, Monoclonal Phase 3,Phase 2
50 Etoposide phosphate Phase 3,Phase 2,Phase 1

Interventional clinical trials:

(show top 50) (show all 188)
# Name Status NCT ID Phase Drugs
1 Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia in Remission Unknown status NCT00454168 Phase 3
2 Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Unknown status NCT00091234 Phase 2, Phase 3 gemtuzumab ozogamicin
3 Combination Chemotherapy Followed by Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00002549 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mesna;mitoxantrone hydrochloride
4 Combination Chemotherapy With or Without Monoclonal Antibody Therapy in Treating Patients With Refractory or Relapsed Acute Myelogenous Leukemia Unknown status NCT00006045 Phase 3 cytarabine;etoposide;mitoxantrone hydrochloride
5 Combination Chemotherapy, Biological Therapy, and Bone Marrow Transplantation in Treating Patients With Acute Myeloid Leukemia Unknown status NCT00002658 Phase 3 amsacrine;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin
6 Combination Chemotherapy, Interleukin-2, and Peripheral Stem Cell Transplant in Treating Patients With Acute Myeloid Leukemia Unknown status NCT00004128 Phase 3 busulfan;cyclophosphamide;cytarabine;daunorubicin hydrochloride;etoposide
7 Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00006363 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar;busulfan
8 Tipifarnib in Treating Patients With Acute Myeloid Leukemia in Remission Completed NCT00093470 Phase 3 Tipifarnib
9 Combination Chemotherapy With or Without Valspodar in Treating Patients With Previously Untreated Acute Myeloid Leukemia Completed NCT00003190 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar
10 Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Children With Acute Myelogenous Leukemia or Myelodysplastic Syndrome Completed NCT00002798 Phase 3 asparaginase;daunorubicin hydrochloride;fludarabine phosphate;therapeutic hydrocortisone;cytarabine;idarubicin;dexamethasone;thioguanine;etoposide;methotrexate;cyclophosphamide;busulfan
11 Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00372593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;etoposide;gemtuzumab ozogamicin;mitoxantrone hydrochloride
12 Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00369317 Phase 3 asparaginase;daunorubicin hydrochloride;cytarabine;thioguanine;etoposide
13 Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia Completed NCT00005863 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;fludarabine phosphate;tretinoin
14 Cytarabine and Daunorubicin With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00121303 Phase 3 cytarabine;daunorubicin hydrochloride;gemtuzumab ozogamicin
15 Chemotherapy With or Without Gemtuzumab Ozogamicin in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00052299 Phase 3 cytarabine;etoposide;gemtuzumab ozogamicin;idarubicin;mitoxantrone hydrochloride
16 Daunorubicin & Cytarabine +/- Zosuquidar inTreating Older Patients With Newly Diagnosed Acute Myeloid Leukemia or Refractory Anemia Completed NCT00046930 Phase 3 cytarabine;daunorubicin hydrochloride;zosuquidar trihydrochloride;Placebo
17 S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML Completed NCT00085709 Phase 3 gemtuzumab ozogamicin;Cytosine arabinoside;Daunomycin
18 Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Completed NCT00454480 Phase 2, Phase 3 arsenic trioxide;azacitidine;busulfan;clofarabine;cytarabine;daunorubicin hydrochloride;fludarabine phosphate;gemtuzumab ozogamicin;melphalan;tipifarnib
19 Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia Completed NCT00112554 Phase 3 cytarabine;laromustine
20 Combination Chemotherapy With or Without G-CSF in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00002719 Phase 3 amsacrine;carmustine;cytarabine;etoposide;idarubicin;mitoxantrone hydrochloride
21 flt3L in Treating Patients With Acute Myeloid Leukemia Completed NCT00006223 Phase 3
22 Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
23 Chemotherapy in Treating Children With Down Syndrome and Myeloproliferative Disorder, Acute Myelogenous Leukemia, or Myelodysplastic Syndrome Completed NCT00003593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;methotrexate;therapeutic hydrocortisone;thioguanine
24 Combination Chemotherapy in Treating Children With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00002517 Phase 3 cytarabine;daunorubicin hydrochloride;dexamethasone;etoposide;idarubicin;mitoxantrone hydrochloride;thioguanine
25 High Dose Chemotherapy, Peripheral Stem Cell Transplantation, and Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00002945 Phase 3 cyclophosphamide;cytarabine;etoposide;idarubicin;melphalan
26 Caspofungin Acetate or Fluconazole in Preventing Invasive Fungal Infections in Patients With Acute Myeloid Leukemia Who Are Undergoing Chemotherapy Active, not recruiting NCT01307579 Phase 3 caspofungin acetate;fluconazole
27 Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting NCT02085408 Phase 3 clofarabine;daunorubicin hydrochloride;cytarabine;decitabine
28 Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting NCT00651261 Phase 3 cytarabine;daunorubicin;midostaurin;dexamethasone acetate
29 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
30 Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Who Have Undergone Stem Cell Transplant Unknown status NCT02038153 Phase 1, Phase 2 Lenalidomide
31 Combination Chemotherapy Plus Biological Therapy in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00003405 Phase 2 amifostine trihydrate;bromodeoxyuridine;cytarabine;idarubicin;idoxuridine;isotretinoin;mitoxantrone hydrochloride
32 Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous Leukemia Unknown status NCT00003758 Phase 2 cytarabine;idarubicin
33 Clofarabine, Cytarabine, and Idarubicin in Treating Patients With Intermediate-Risk or High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplasia Unknown status NCT00838240 Phase 1, Phase 2 clofarabine;cytarabine;idarubicin
34 VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia Unknown status NCT00354276 Phase 2 cytarabine;laromustine
35 Bexarotene and GM-CSF in Treating Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Unknown status NCT00425477 Phase 2 bexarotene
36 Monoclonal Antibody in Treating Patients With Acute Myelogenous Leukemia Unknown status NCT00006084 Phase 2
37 Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia Completed NCT00666588 Phase 2 idarubicin;cytarabine;bortezomib;etoposide
38 High-Dose Busulfan and High-Dose Cyclophosphamide Followed By Donor Bone Marrow Transplant in Treating Patients With Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Recurrent Hodgkin or Non-Hodgkin Lymphoma Completed NCT01177371 Phase 2 busulfan;cyclophosphamide;methylprednisolone;methotrexate;cyclosporine
39 Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies Completed NCT01093586 Phase 2 busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil
40 Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Completed NCT00027872 Phase 2 tipifarnib
41 Cytarabine With or Without SCH 900776 in Treating Adult Patients With Relapsed Acute Myeloid Leukemia Completed NCT01870596 Phase 2 Cytarabine;CHK1 Inhibitor SCH 900776
42 Tipifarnib in Treating Older Patients With Acute Myeloid Leukemia Completed NCT01361464 Phase 2 Tipifarnib
43 Choline Magnesium Trisalicylate and Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia Completed NCT02144675 Phase 2 choline magnesium trisalicylate;idarubicin;cytarabine
44 Alvocidib, Cytarabine, and Mitoxantrone Hydrochloride or Cytarabine and Daunorubicin Hydrochloride in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT01349972 Phase 2 alvocidib;daunorubicin hydrochloride;mitoxantrone hydrochloride;cytarabine
45 AKT Inhibitor MK-2206 in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed NCT01253447 Phase 2 Akt inhibitor MK2206
46 Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy Completed NCT01235572 Phase 2
47 Vorinostat, Azacitidine, and Gemtuzumab Ozogamicin for Older Patients With Relapsed or Refractory AML Completed NCT00895934 Phase 1, Phase 2 vorinostat;gemtuzumab ozogamicin;azacitidine
48 Comparing Three Different Combination Chemotherapy Regimens in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed NCT00634244 Phase 2 alvocidib;mitoxantrone hydrochloride;carboplatin;cytarabine;sirolimus;etoposide;topotecan hydrochloride
49 Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00795002 Phase 2 alvocidib;mitoxantrone hydrochloride;cytarabine
50 Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Completed NCT00742625 Phase 1, Phase 2 daunorubicin hydrochloride;cytarabine;bortezomib

Search NIH Clinical Center for Monocytic Leukemia

Genetic Tests for Monocytic Leukemia

Anatomical Context for Monocytic Leukemia

MalaCards organs/tissues related to Monocytic Leukemia:

41
Myeloid, Monocytes, Bone, Bone Marrow, Skin, Lung, Prostate

Publications for Monocytic Leukemia

Articles related to Monocytic Leukemia:

(show top 50) (show all 546)
# Title Authors Year
1
Cellular internalization and antioxidant activity of cerium oxide nanoparticles in human monocytic leukemia cells. ( 29593393 )
2018
2
Anti-Leukemic Properties of Histamine in Monocytic Leukemia: The Role of NOX2. ( 29967760 )
2018
3
Anti-Cancerous Effect of Inonotus taiwanensis Polysaccharide Extract on Human Acute Monocytic Leukemia Cells through ROS-Independent Intrinsic Mitochondrial Pathway. ( 29382173 )
2018
4
Suppressive effects of metformin on T-helper 1-related chemokines expression in the human monocytic leukemia cell line THP-1. ( 29630425 )
2018
5
Trisomy 6 as the sole stemline abnormality in a patient with acute monocytic leukemia: a case report. ( 29755835 )
2018
6
Dihydroartemisinin-induced apoptosis in human acute monocytic leukemia cells. ( 29435054 )
2018
7
Haemophagocytic lymphohistiocytosis occurred during induction chemotherapy in an acute monocytic leukemia patient with FLT3-ITD and DNMT3A mutations. ( 29843647 )
2018
8
Acute monocytic leukemia diagnosed by flow cytometry includes acute myeloid leukemias with weakly or faintly positive non-specific esterase staining. ( 29721252 )
2018
9
Bone Marrow Adipocytes Facilitate Fatty Acid Oxidation Activating AMPK and a Transcriptional Network Supporting Survival of Acute Monocytic Leukemia Cells. ( 28108519 )
2017
10
Duplication of subtelomeric regions in an adult with acute monocytic leukemia with an acquired jumping translocation involving 3q13.31-qter. ( 28725672 )
2017
11
Cutaneous presentation preceding acute monocytic leukemia: A CARE-compliant article. ( 28272239 )
2017
12
Upregulation of long non-coding RNA MALAT-1 confers poor prognosis and influences cell proliferation and apoptosis in acute monocytic leukemia. ( 28713913 )
2017
13
C59T mutation in exon 2 of monocytic leukemia-associated antigen-34 gene indicates a high risk of recurrence of acute myeloid leukemia. ( 28693135 )
2017
14
The Marine Natural Product Pseudopterosin Blocks Cytokine Release of Triple-Negative Breast Cancer and Monocytic Leukemia Cells by Inhibiting NF-I_B Signaling. ( 28832545 )
2017
15
5-Aminoimidazole-4-carboxamide ribonucleoside-induced autophagy flux during differentiation of monocytic leukemia cells. ( 28975042 )
2017
16
Treatment-related acute granulocyte-monocytic leukemia from multiple myeloma: A case report and literature review. ( 29390389 )
2017
17
Upregulation of CD11b and CD86 through LSD1 inhibition promotes myeloid differentiation and suppresses cell proliferation in human monocytic leukemia cells. ( 29156705 )
2017
18
5a89azaa892'a89deoxycytidine promotes migration of acute monocytic leukemia cells via activation of CCL2a89CCR2a89ERK signaling pathway. ( 28627644 )
2017
19
Cooperation of MLL/AF10(OM-LZ) with PTPN11 activating mutation induced monocytic leukemia with a shorter latency in a mouse bone marrow transplantation model. ( 27859216 )
2017
20
Cordycepin induces apoptosis of human acute monocytic leukemia cells via downregulation of the ERK/Akt signaling pathway. ( 28912858 )
2017
21
Characterization of an acquired jumping translocation involving 3q13.31-qter in a patient with de novo acute monocytic leukemia. ( 28625614 )
2017
22
Jab1/Csn5-Thioredoxin Signaling in Relapsed Acute Monocytic Leukemia under Oxidative Stress. ( 28270496 )
2017
23
Lineage switch from B acute lymphoblastic leukemia to acute monocytic leukemia with persistent t(4;11)(q21;q23) and cytogenetic evolution under CD19-targeted therapy. ( 28634616 )
2017
24
Polydatin Induces Apoptosis and Inhibits Growth of Acute Monocytic Leukemia Cells. ( 26616494 )
2016
25
Leukemia cutis preceding bone marrow relapse in acute monocytic leukemia. ( 27643547 )
2016
26
Hypoxia inducible factor-1a regulates a pro-invasive phenotype in acute monocytic leukemia. ( 27447550 )
2016
27
Acute Monocytic Leukemia Masquerading BehAset's Disease-Like Illness at Onset in an Elderly Female. ( 27610252 )
2016
28
Spurious Thrombocytosis Caused by Tumor Cell Lysis in a Patient with Acute Monocytic Leukemia. ( 28164618 )
2016
29
Acute monocytic leukemia masked by hemolytic anemia and sclerotic lesions. ( 27572458 )
2016
30
Histiocytic differentiation in acute monocytic leukemia. ( 26771450 )
2016
31
Knockdown of p54nrb inhibits migration, invasion and TNF-I+ release of human acute monocytic leukemia THP1 cells. ( 27108701 )
2016
32
A Wnt pathway activator induces apoptosis and cell death in mouse monocytic leukemia cells. ( 27623760 )
2016
33
The Successful Complete Remission Induction by Sorafenib Monotherapy in a FLT3-D835Y-Positive Patient with Refractory Acute Monocytic Leukemia. ( 27408351 )
2016
34
Suppression of NRF2-ARE activity sensitizes chemotherapeutic agent-induced cytotoxicity in human acute monocytic leukemia cells. ( 26708503 )
2016
35
Antioxidation and antiproliferation of ethanol extracts from edible mushrooms against U937 human monocytic leukemia cells. ( 27976050 )
2016
36
Generation of a MLL-AF9-specific stem cell model of acute monocytic leukemia. ( 27185517 )
2016
37
Curcumin induces apoptosis and suppresses invasion through MAPK and MMP signaling in human monocytic leukemia SHI-1 cells. ( 26134921 )
2015
38
Nitric oxide is the key mediator of death induced by fisetin in human acute monocytic leukemia cells. ( 25973292 )
2015
39
Ara-C and anti-CD47 antibody combination therapy eliminates acute monocytic leukemia THP-1 cells in vivo and in vitro. ( 26125761 )
2015
40
Pathways related to PMA-differentiated THP1 human monocytic leukemia cells revealed by RNA-Seq. ( 26582014 )
2015
41
Histiocytic sarcoma combined with acute monocytic leukemia: a case report. ( 26187047 )
2015
42
Autocrine motility factor receptor promotes the proliferation of human acute monocytic leukemia THP-1 cells. ( 26136223 )
2015
43
Alkaline phosphatase is a useful cytochemical marker for the diagnosis of acute myelomonocytic and monocytic leukemia in the dog. ( 25546124 )
2015
44
Induction with azacytidine followed by allogeneic hematopoietic stem cell transplantation in a Jehovah's Witness with acute monocytic leukemia. ( 25984306 )
2015
45
Hypomethylating agents as bridging therapy before allogeneic hematopoietic stem cell transplant in patients with chronic myelo-monocytic leukemia (CMML) ? ( 26576835 )
2015
46
A case of extramedullary involvement of acute monocytic leukemia that presented as obstructive jaundice. ( 26422978 )
2015
47
Posterior reversible encephalopathy syndrome following acute pancreatitis during chemotherapy for acute monocytic leukemia. ( 24881921 )
2014
48
Spontaneous regression of cutaneous blastic plasmacytoid dendritic cell neoplasm followed by acute monocytic leukemia evolving from myelodysplastic syndrome. ( 25447656 )
2014
49
Secondary acute monocytic leukemia positive for 11q23 rearrangement in Nijmegen breakage syndrome. ( 24619942 )
2014
50
Modulation of monocytic leukemia cell function and survival by high gradient magnetic fields and mathematical modeling studies. ( 24439412 )
2014

Variations for Monocytic Leukemia

Expression for Monocytic Leukemia

Search GEO for disease gene expression data for Monocytic Leukemia.

Pathways for Monocytic Leukemia

Pathways related to Monocytic Leukemia according to GeneCards Suite gene sharing:

(show top 50) (show all 90)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.1 CASP3 CD14 CSF1 CSF2 CXCL8 IFNG
2
Show member pathways
13.92 CASP3 CSF1 CSF2 CXCL8 IL1B IL6
3
Show member pathways
13.76 CASP3 CD14 CSF1 CSF2 CXCL8 IFNG
4
Show member pathways
13.55 CXCL8 IFNG IL1B IL6 ITGAM JUN
5
Show member pathways
13.49 CASP3 CSF1 CSF2 CXCL8 IL1B IL6
6
Show member pathways
13.46 CASP3 CSF1 CSF2 CXCL8 IFNG IL1B
7
Show member pathways
13.39 CASP3 CSF1 CSF2 CXCL8 IL1B IL6
8
Show member pathways
13.11 CD14 CXCL8 IFNG IL1B IL6 JUN
9
Show member pathways
12.96 CASP3 CXCL8 IFNG IL1B IL6 TNF
10
Show member pathways
12.95 CASP3 CD14 CSF2 ITGAM JUN PPARG
11 12.93 CASP3 CXCL8 IFNG IL6 JUN PPARG
12
Show member pathways
12.9 CASP3 CXCL8 IFNG IL1B IL6 JUN
13 12.87 CASP3 CD14 CSF1 IL1B JUN TNF
14
Show member pathways
12.86 CD14 CXCL8 IFNG IL1B IL6 TNF
15
Show member pathways
12.84 CD14 IFNG IL1B JUN TNF
16
Show member pathways
12.75 CSF2 CXCL8 IFNG IL1B IL6 TNF
17
Show member pathways
12.74 CASP3 IFNG IL1B JUN TNF
18
Show member pathways
12.69 CASP3 CSF2 CXCL8 IL6 JUN TNF
19
Show member pathways
12.67 CD14 IFNG IL1B IL6 TNF
20
Show member pathways
12.61 CASP3 CSF2 IFNG JUN TNF
21
Show member pathways
12.58 CASP3 IL1B JUN TNF
22
Show member pathways
12.55 IFNG IL1B IL6 JUN TNF
23
Show member pathways
12.55 CSF2 IFNG IL1B IL6 JUN TNF
24 12.47 CSF2 IL6 JUN TNF
25
Show member pathways
12.47 CASP3 CSF2 CXCL8 IFNG IL1B IL6
26
Show member pathways
12.44 CSF1 IFNG IL1B IL6 TNF
27
Show member pathways
12.41 CD14 CXCL8 IFNG IL1B IL6 JUN
28 12.4 CD14 CSF2 CXCL8 IL6 ITGAM KMT2A
29
Show member pathways
12.39 CASP3 IFNG IL1B ITGAM JUN TNF
31
Show member pathways
12.38 CD14 CXCL8 IL6 JUN TNF
32
Show member pathways
12.37 IFNG IL1B IL6 JUN TNF
33 12.37 CASP3 CD14 IFNG IL1B IL6 ITGAM
34
Show member pathways
12.36 CXCL8 F3 IL1B IL6 JUN TNF
35 12.32 CASP3 CXCL8 IL1B IL6 JUN TNF
36
Show member pathways
12.32 CD14 CXCL8 IFNG IL1B IL6 JUN
37
Show member pathways
12.29 IL1B IL6 JUN TNF
38 12.27 CASP3 IFNG IL6 TNF
39 12.21 CSF1 IFNG IL1B JUN PPARG TNF
40 12.18 IFNG IL1B JUN TNF
41
Show member pathways
12.16 CXCL8 IFNG IL1B IL6 JUN
42 12.16 CASP3 CXCL8 IFNG IL1B IL6 TNF
43 12.16 CD14 CSF1 CSF2 IFNG IL6 ITGAM
44 12.12 CXCL8 IL1B IL6 ITGAM TNF
45 12.09 CXCL8 IFNG IL1B IL6 JUN KMT2A
46 12.09 CASP3 CSF1 CSF2 IL1B IL6 JUN
47 12.03 CASP3 CXCL8 F3 IL1B IL6 JUN
48 12.01 CD14 CSF1 CSF2 IL1B IL6 ITGAM
49 12 CD14 CXCL8 IL1B TNF
50
Show member pathways
11.99 CD14 CSF2 CXCL8 IL6

GO Terms for Monocytic Leukemia

Cellular components related to Monocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.65 CD14 CSF1 CSF2 CXCL8 F3 IFNG
2 membrane raft GO:0045121 9.56 CASP3 CD14 ITGAM TNF
3 extracellular space GO:0005615 9.32 CD14 CSF1 CSF2 CXCL8 F3 IFNG
4 MOZ/MORF histone acetyltransferase complex GO:0070776 9.16 KAT6A KAT6B

Biological processes related to Monocytic Leukemia according to GeneCards Suite gene sharing:

(show all 47)
# Name GO ID Score Top Affiliating Genes
1 regulation of cell proliferation GO:0042127 9.99 CSF2 CXCL8 JUN TNF
2 negative regulation of cell proliferation GO:0008285 9.99 CXCL8 IL1B IL6 JUN KMT2A PPARG
3 inflammatory response GO:0006954 9.97 CD14 CSF1 CXCL8 IL1B IL6 TNF
4 positive regulation of gene expression GO:0010628 9.95 CSF1 CSF2 IFNG IL1B IL6 TNF
5 negative regulation of transcription, DNA-templated GO:0045892 9.91 CSF2 IFNG JUN KAT6A KAT6B PPARG
6 positive regulation of DNA binding transcription factor activity GO:0051091 9.88 IL1B IL6 PPARG TNF
7 apoptotic signaling pathway GO:0097190 9.86 CASP3 CD14 TNF
8 cellular response to organic cyclic compound GO:0071407 9.86 CASP3 IL1B TNF
9 regulation of insulin secretion GO:0050796 9.85 IFNG IL1B TNF
10 response to organic substance GO:0010033 9.85 CASP3 JUN PPARG TNF
11 response to lipopolysaccharide GO:0032496 9.85 CASP3 CD14 CXCL8 IL1B JUN
12 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.84 CSF2 IFNG IL6
13 response to glucocorticoid GO:0051384 9.84 CASP3 IL6 TNF
14 activation of cysteine-type endopeptidase activity involved in apoptotic process GO:0006919 9.84 CASP3 F3 PPARG TNF
15 humoral immune response GO:0006959 9.83 IFNG IL6 TNF
16 positive regulation of smooth muscle cell proliferation GO:0048661 9.83 IL6 JUN TNF
17 positive regulation of interleukin-6 production GO:0032755 9.82 IL1B IL6 TNF
18 positive regulation of NIK/NF-kappaB signaling GO:1901224 9.8 CD14 IL1B TNF
19 positive regulation of interferon-gamma production GO:0032729 9.8 CD14 IL1B TNF
20 regulation of signaling receptor activity GO:0010469 9.8 CSF1 CSF2 CXCL8 IFNG IL1B IL6
21 positive regulation of nitric oxide biosynthetic process GO:0045429 9.78 IFNG IL1B TNF
22 negative regulation of extrinsic apoptotic signaling pathway in absence of ligand GO:2001240 9.77 CSF2 IL1B TNF
23 lipopolysaccharide-mediated signaling pathway GO:0031663 9.77 CD14 IL1B TNF
24 positive regulation of transcription, DNA-templated GO:0045893 9.76 IL1B IL6 JUN KAT6A KAT6B KMT2A
25 cellular response to lipopolysaccharide GO:0071222 9.72 CD14 CSF2 CXCL8 IL6 TNF
26 microglial cell activation GO:0001774 9.7 ITGAM JUN
27 negative regulation of collagen biosynthetic process GO:0032966 9.7 IL6 PPARG
28 response to molecule of bacterial origin GO:0002237 9.7 CD14 CXCL8
29 positive regulation of osteoclast differentiation GO:0045672 9.7 CSF1 IFNG TNF
30 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.69 IL1B TNF
31 positive regulation of podosome assembly GO:0071803 9.69 CSF2 TNF
32 negative regulation of lipid storage GO:0010888 9.68 IL6 TNF
33 positive regulation of monocyte differentiation GO:0045657 9.68 CSF1 JUN
34 positive regulation of chemokine biosynthetic process GO:0045080 9.67 IL1B TNF
35 regulation of establishment of endothelial barrier GO:1903140 9.66 IL1B TNF
36 positive regulation of fever generation GO:0031622 9.64 IL1B TNF
37 positive regulation of interleukin-23 production GO:0032747 9.63 CSF2 IFNG
38 sequestering of triglyceride GO:0030730 9.61 IL1B TNF
39 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.61 IFNG IL1B TNF
40 monocyte differentiation GO:0030224 9.58 CSF2 JUN PPARG
41 positive regulation of vitamin D biosynthetic process GO:0060557 9.57 IFNG TNF
42 cytokine-mediated signaling pathway GO:0019221 9.28 CASP3 CSF1 CSF2 CXCL8 F3 IL1B
43 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.13 IFNG IL1B TNF
44 positive regulation of transcription by RNA polymerase II GO:0045944 10.19 IL1B IL6 JUN KAT6B KMT2A PPARG
45 positive regulation of cell proliferation GO:0008284 10.06 CSF1 CSF2 IFNG IL1B IL6 JUN
46 immune response GO:0006955 10.03 CSF2 CXCL8 IFNG IL1B IL6 TNF
47 positive regulation of apoptotic process GO:0043065 10.02 CASP3 IL6 JUN PPARG TNF

Molecular functions related to Monocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 9.89 CASP3 CD14 CSF1 CSF2 CXCL8 F3
2 transcription regulatory region DNA binding GO:0044212 9.46 JUN KMT2A PPARG TNF
3 cytokine activity GO:0005125 9.17 CSF1 CSF2 CXCL8 IFNG IL1B IL6

Sources for Monocytic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....